• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Quince Therapeutics Inc. (Amendment)

    2/7/24 10:50:14 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $QNCX alert in real time by email
    SC 13G/A 1 qncx13g020724.htm

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G/A*
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED
    IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND
    (d) AND AMENDMENTS THERETO
    FILED PURSUANT TO RULE 13d-2
    (AMENDMENT NO.  1   )*

    Quince Therapeutics, Inc. 
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
     22053A107
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

     
    1
    NAMES OF REPORTING PERSONS
     
     
     BML Investment Partners, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     0.0
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     PN
     
     
     
     
     
    1
    NAMES OF REPORTING PERSONS
     
     
     Braden M Leonard
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     0.0
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     IN
     
     
     
     

    Item 1(a). Name of Issuer:

     Quince Therapeutics, Inc.
     
    Item 1(b). Address of Issuer's Principal Executive Offices:

     601 Gateway Boulevard, Suite 1250, South San Francisco, CA 94080

    Item 2(a). Name of Person Filing:

     

    BML Investment Partners, L.P

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     65 Cedar - Suite 2
    Zionsville, IN 46077

    Item 2(c). Citizenship:

     Delaware

    Item 2(d). Title of Class of Securities:

     

    Common Stock, par value $0.001 per share
     
    Item 2(e). CUSIP Number:


    22053A107
     


    Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
    240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):


    (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);


    (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);


    (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


    (e) ☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


    (f) ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);


    (g) ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


    (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


    (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j) ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


    (k) ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .
     
    Item 4. Ownership.


    (a) Amount beneficially owned: 0


    (b) Percent of class:0


    (c) Number of shares as to which the person has:


    (i) Sole power to vote or to direct the vote:0


    (ii) Shared power to vote or to direct the vote:0

      (iii) Sole power to dispose or to direct the disposition of:0

      (iv) Shared power to dispose or to direct the disposition of:0
     


    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

    N/A
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     N/A

    Item 8. Identification and Classification of Members of the Group.

     N/A

    Item 9. Notice of Dissolution of Group.

     N/A
     
    Item 10.
    Certification.
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 7, 2024
     
      BML Capital Management, LLC
     
     
    By:
     /s/ Braden M Leonard
       
    Name:  Braden M Leonard
       
    Title:  Managing Member
     
     
     

    Get the next $QNCX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $QNCX

    DatePrice TargetRatingAnalyst
    3/24/2025$10.00Outperform
    Oppenheimer
    More analyst ratings

    $QNCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO AND CHIEF MEDICAL OFFICER Thye Dirk bought $107,375 worth of shares (154,500 units at $0.69), increasing direct ownership by 22% to 843,941 units (SEC Form 4)

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      9/3/24 5:38:44 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PRESIDENT Ryan Charles S. bought $31,452 worth of shares (48,387 units at $0.65), increasing direct ownership by 65% to 122,461 units (SEC Form 4)

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      8/22/24 5:51:16 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF BUSINESS OFFICER AND COO Hannah Brendan bought $24,166 worth of shares (38,924 units at $0.62), increasing direct ownership by 15% to 296,540 units (SEC Form 4)

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      8/21/24 6:38:07 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

      Phase 3 NEAT enrollment momentum continues with 99 total participants enrolled to date Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced its participation at the upcoming 2025 A-T Clinical Research Conference organized by the A-T Society, a leading Ataxia-Telangiectasia (A-T) patient advocacy group based in the United Kingdom. Taking place June 25-27, 2025 at Loughborough University in the U.K., key opinion leaders (KOLs) will present post hoc data analyses from the company's prior Phase 3 ATTeST clinical trial of its lead asset, eDSP, for the treatment

      6/25/25 4:05:00 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

      Financing priced at a premium; led by healthcare-focused institutional investor Nantahala Capital with participation from existing Quince stockholders including ADAR1 Capital Management, along with members of Quince's senior management Cash runway now extends through Phase 3 NEAT into at least the second quarter of 2026 Phase 3 NEAT enrollment momentum continues with 95 total participants enrolled to date; topline results expected in first quarter of 2026 Quince Therapeutics, Inc. (NASDAQ:QNCX) ("Quince" or the "Company"), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the closing of it

      6/18/25 4:05:00 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

      Financing to provide $11.5 million in upfront proceeds with up to an additional $10.4 million of proceeds assuming exercise in full of the warrants Financing priced at a premium to last close Quince Therapeutics, Inc. (NASDAQ:QNCX) ("Quince" or the "Company"), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors to purchase shares of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants ("Warrants") that is expected to result in approximately $11.5 m

      6/12/25 5:15:00 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    SEC Filings

    See more
    • SEC Form D filed by Quince Therapeutics Inc.

      D - Quince Therapeutics, Inc. (0001662774) (Filer)

      7/1/25 2:20:32 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

      8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

      6/13/25 5:25:18 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Quince Therapeutics Inc.

      8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

      6/5/25 4:12:42 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CBO, COO & CCO Hannah Brendan was granted 37,736 shares, increasing direct ownership by 13% to 334,276 units (SEC Form 4)

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      6/23/25 8:48:00 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President Ryan Charles S. was granted 7,548 shares, increasing direct ownership by 6% to 130,009 units (SEC Form 4)

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      6/23/25 8:46:04 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO and CMO Thye Dirk was granted 150,944 shares, increasing direct ownership by 18% to 994,885 units (SEC Form 4)

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      6/23/25 8:43:12 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Leadership Updates

    Live Leadership Updates

    See more
    • Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. William Whitehouse, Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, and recently retired Consultant Paediatric Neurologist at Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust, to the company's Scientific Advisory Board (SAB). Dr. Whitehouse joins seven founding members of Quince's SAB comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice. Dr. Mauro Magn

      1/23/25 4:05:00 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced the appointment of Rajiv Patni, M.D., a biopharma industry veteran and global product development expert, to the company's Board of Directors. "We are pleased to welcome a proven clinical development leader of Dr. Rajiv Patni's caliber to our Board of Directors," said David Lamond, chairperson of Quince's Board of Directors. "With expertise that spans the continuum from translational to registrational studies and regulatory agency negotiation in several rare diseases, we lo

      2/15/24 7:00:00 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Appoints Dr. Charles S. Ryan as President

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President. In this new position, Dr. Ryan will be responsible for the company's corporate legal activities and intellectual property portfolio, and pending the completion of its planned acquisition of EryDel S.p.A., the international integration of financial and operational activities and ongoing business operations of Quince. Dirk Thye, M.D., Quince's Chief Executive Officer, said, "Charles is a valuable addition to our management team. His considera

      9/6/23 7:00:00 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

      SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)

      11/14/24 4:00:05 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Quince Therapeutics Inc.

      SC 13D - Quince Therapeutics, Inc. (0001662774) (Subject)

      11/13/24 9:17:26 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

      SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)

      8/6/24 8:04:44 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Financials

    Live finance-specific insights

    See more
    • Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that its Board of Directors (the "Board") unanimously approved the adoption of a limited duration stockholder rights plan (the "Rights Plan") and declared a dividend distribution of one preferred share purchase right on each outstanding share of Quince's common stock. The dividend distribution will be made on April 17, 2023, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on April 5, 2024.

      4/5/23 4:05:00 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Quince Therapeutics with a new price target

      Oppenheimer initiated coverage of Quince Therapeutics with a rating of Outperform and set a new price target of $10.00

      3/24/25 8:40:42 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care